Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- BetterLife Pharma Inc.BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsBetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta...
- Theralase Technologies Inc.Theralase(R) Closes C$3.6 Million Brokered FinancingTheralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500...
- Rocket Doctor Grants EquityRocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”) announces that it has granted an aggregate 24,000 stock options, exercisable at $0.70 per share and valid for a term of three years, and an aggregate 276,053 restricted share units, valid for a term between one to three years, to consultants of the Company and its subsidiary. The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and 96,000 restricted share units and all stock options are subject to vesting over one year. All securities are subject to a hold period of four months and one day in accordance with applicable securities laws and policies of the Canadian Securities Exchange. About Rocket Doctor AI Inc. Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide. Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care. By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered. To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: [email protected] FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO, Rocket Doctor AI [email protected] Dr. Bill Cherniak, CEO, Rocket Doctor Inc. [email protected] For media inquiries, contact: [email protected] Call: +1 (778) 819 8321 Cautionary Statements This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the granting of stock options and restricted share units to consultants, the terms and vesting conditions of such stock options and restricted share units, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include the risk that the stock options or restricted share units may not vest on the anticipated terms, risks related to the Company’s share compensation plan, and other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
- Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial ResultsVAUGHAN, Ontario, August 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.
- Tampa General HospitalTGH Brooksville Performs First Cardiothoracic Surgery, Expanding Access to Advanced Heart Care in Hernando CountyThis milestone brings complex cardiothoracic surgical care closer to home for patients in Hernando County and surrounding communities, backed by the expertise and resources of Tampa General's academic health system. TAMPA, Fla., Aug. 24, 2026 -- Tampa General Hospital (TGH)...
- Savara Inc.Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
- Dimora MedicalDimora Medical Introduces New Pricing for MegaSorb™ Dressings, Expanding Access to Professional-Grade Wound CareDimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more...
- Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fractyl Health, Inc. (GUTS)Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) securities between January 13, 2025 through January 29, 2026,, inclusive (the “Class Period”).
- Robbins LLPDid You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARDShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company...
- National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other ClaimsNew York, NY – August 24, 2026 – In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National […]
- Number of Shares and Voting Rights of ADOCIA as of July 31st, 2026LYON, France, August 24, 2026--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the "Company") a clinical-stage biopharmaceutical company focused on the research and development of i
- GUTS INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Fractyl Health, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmA shareholder class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl”) (NASDAQ: GUTS). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; and (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy.